EICHORCondition: Pain, Postoperative · Sponsor: Neumentum, Inc.
This clinical study is a randomized, double-blind, double-dummy, parallel group, multi-center, active and placebo-controlled trial evaluating the analgesic efficacy and safety of NTM-001 in subjects with moderately severe postoperative pain after bunionectomy surgery. This study is designed to compare the efficacy of NTM-001 to placebo. Intravenous (IV) morphine serves as an active comparator to determine assay sensitivity and support assessment of opioid-level analgesia for NTM-001. Effectiveness, safety, and tolerability parameters will be descriptively compared between treatment arms.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Sun City Clinical Research | Sun City, Arizona, United States | — |
| Trovare Clinical Research | Bakersfield, California, United States | — |
| Alliance Research Intitute | Canoga Park, California, United States | — |
| Pasadena Clinical Trials | Pomona, California, United States | — |
| Dr. Vince Clinical Research | Overland Park, Kansas, United States | — |
| Chesapeake Research | Pasadena, Maryland, United States | — |
| Curalta Clinical Trials | Westwood, New Jersey, United States | — |
| Midwest Clinical Research Center | Dayton, Ohio, United States | — |
| The Orthopedic Center | Tulsa, Oklahoma, United States | — |
| Endeavor Clinical Trials | San Antonio, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05324358